Marathon Pharmaceuticals announced that the Food and Drug Administration (FDA) has granted Fast Track designation to deflazacort for the treatment of patients with Duchenne Muscular Dystrophy (DMD). Deflazacort is a glucocorticoid with anti-inflammatory and immunosuppressant properties.

RELATED: Musculoskeletal Disorders Resource Center

Currently numerous clinical and preclinical studies of deflazacort are underway to support approval in patients with DMD. Maraton plans on submitting a New Drug Application (NDA) in early 2016. The FDA previously granted Orphan Drug designation to deflazacort for the treatment of DMD.

For more information visit Marathonpharma.com.


Continue Reading